|
ZA978515B
(en)
*
|
1996-09-23 |
1999-03-23 |
Lilly Co Eli |
Intermediates and process for preparing olanzapine
|
|
US6617321B2
(en)
|
1997-09-30 |
2003-09-09 |
Eli Lilly And Company |
2-methyl-thieno-benzodiazepine formulation
|
|
AU759751B2
(en)
*
|
1998-09-30 |
2003-05-01 |
Eli Lilly And Company |
2-methyl-thieno-benzodiazepine formulation
|
|
PT1246827E
(pt)
*
|
1999-12-28 |
2005-08-31 |
Cipla Ltd |
Novas formas polimerficas da olanzapina
|
|
US7022698B2
(en)
|
1999-12-28 |
2006-04-04 |
U & I Pharmaceuticals, Ltd. |
Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
|
|
CA2420987A1
(en)
*
|
2000-08-31 |
2002-03-07 |
Dr. Reddy's Laboratories Ltd. |
Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
|
|
US6740753B2
(en)
|
2001-01-04 |
2004-05-25 |
Geneva Pharmaceuticals, Inc. |
Olanzapine crystal modification
|
|
CA2464306A1
(en)
*
|
2001-10-29 |
2003-05-08 |
Dr. Reddy's Laboratories Ltd. |
Olanzapine dihydrate-ii a process for its preparation and use thereof
|
|
US7297789B2
(en)
|
2002-05-31 |
2007-11-20 |
Sandoz, Inc. |
Process of preparation of olanzapine form I
|
|
SI21270A
(sl)
|
2002-07-15 |
2004-02-29 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Kristalne oblike olanzapina in postopki za njihovo pripravo
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
US7323459B2
(en)
*
|
2002-12-24 |
2008-01-29 |
Teva Pharmaceutical Industries Ltd. |
Crystal forms, methods for their preparation and method for preparation of olanzapine
|
|
US6861422B2
(en)
|
2003-02-26 |
2005-03-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
|
JP2007511605A
(ja)
*
|
2003-11-18 |
2007-05-10 |
スリーエム イノベイティブ プロパティズ カンパニー |
オランザピン含有経皮薬物送達組成物
|
|
ATE504588T1
(de)
|
2004-01-27 |
2011-04-15 |
Synthon Bv |
Stabile salze von olanzapin
|
|
DE102004029784A1
(de)
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
|
|
DE102004030502A1
(de)
|
2004-06-24 |
2006-01-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
|
|
DE102004033670A1
(de)
|
2004-07-09 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
|
|
EP1781666A1
(en)
*
|
2004-07-14 |
2007-05-09 |
Shasun Chemicals and Drugs Limited |
Improved process for making form i of olanzapine.
|
|
US20060074088A1
(en)
|
2004-08-14 |
2006-04-06 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones for the treatment of cancer diseases
|
|
US20060035903A1
(en)
|
2004-08-14 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Storage stable perfusion solution for dihydropteridinones
|
|
US7759485B2
(en)
|
2004-08-14 |
2010-07-20 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of dihydropteridinones
|
|
US7728134B2
(en)
|
2004-08-14 |
2010-06-01 |
Boehringer Ingelheim International Gmbh |
Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
|
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
|
EP1630163A1
(de)
|
2004-08-25 |
2006-03-01 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
|
ES2303462B1
(es)
|
2004-09-06 |
2009-06-05 |
Shasun Chemicals And Drugs Limited |
Nuevo procedimiento para la preparacion de una forma polimorfica i de olanzapina farmaceuticamente pura.
|
|
AU2005289100B2
(en)
|
2004-09-29 |
2011-11-03 |
Bayer Healthcare Llc |
Thermodynamically stable form of bay 43-9006 tosylate
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
EP2623095A1
(en)
*
|
2004-11-16 |
2013-08-07 |
Elan Pharma International Limited |
Injectable nanoparticulate olanzapine formulations
|
|
DE102004058337A1
(de)
|
2004-12-02 |
2006-06-14 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
|
|
EP1838716B1
(en)
|
2005-01-05 |
2011-06-01 |
Eli Lilly And Company |
Olanzapine pamoate dihydrate
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
US8551986B2
(en)
*
|
2005-12-08 |
2013-10-08 |
The Mclean Hospital Corporation |
Treatment of sequelae of psychiatric disorders
|
|
US7834176B2
(en)
*
|
2006-01-26 |
2010-11-16 |
Sandoz Ag |
Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
|
|
US7439358B2
(en)
|
2006-02-08 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
|
|
BRPI0711558A2
(pt)
|
2006-05-04 |
2011-11-08 |
Boeringer Ingelheim Internat Gmbh |
polimorfos
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
AR062927A1
(es)
|
2006-10-11 |
2008-12-17 |
Bayer Healthcare Ag |
4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
|
|
US8039461B1
(en)
|
2006-11-10 |
2011-10-18 |
Pisgah Laboratories, Inc. |
Physical states of a pharmaceutical drug substance
|
|
US7718649B1
(en)
|
2006-11-10 |
2010-05-18 |
Pisgah Labs, Inc. |
Physical states of a pharmaceutical drug substance
|
|
EP2185559A1
(en)
|
2007-08-03 |
2010-05-19 |
Boehringer Ingelheim International GmbH |
Crystalline form of a dihydropteridione derivative
|
|
US8883863B1
(en)
|
2008-04-03 |
2014-11-11 |
Pisgah Laboratories, Inc. |
Safety of psuedoephedrine drug products
|
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
EP2299983A4
(en)
*
|
2008-07-24 |
2012-10-10 |
Handa Pharmaceuticals Llc |
ATYPICAL ANTIPSYCHOTIC FORMULATION STABILIZED
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
|
AU2009290911A1
(en)
|
2008-09-10 |
2010-03-18 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
EP2382216A1
(en)
|
2008-12-23 |
2011-11-02 |
Boehringer Ingelheim International GmbH |
Salt forms of organic compound
|
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
|
EA034869B1
(ru)
|
2009-11-27 |
2020-03-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
|
|
MX341025B
(es)
|
2010-05-05 |
2016-08-04 |
Boehringer Ingelheim Int Gmbh * |
Terapia de combinacion.
|
|
PH12012502524A1
(en)
|
2010-06-24 |
2014-02-10 |
Boehringer Ingelheim Int |
Diabetes therapy
|
|
US8546566B2
(en)
|
2010-10-12 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Process for manufacturing dihydropteridinones and intermediates thereof
|
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
|
US9370535B2
(en)
|
2011-05-17 |
2016-06-21 |
Boehringer Ingelheim International Gmbh |
Method for treatment of advanced solid tumors
|
|
EP3517539B1
(en)
|
2011-07-15 |
2022-12-14 |
Boehringer Ingelheim International GmbH |
Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
JP6224084B2
(ja)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
|
|
US20130303554A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in sirs and/or sepsis
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
US10154988B2
(en)
|
2012-11-14 |
2018-12-18 |
The Johns Hopkins University |
Methods and compositions for treating schizophrenia
|
|
JP2016027003A
(ja)
*
|
2012-11-20 |
2016-02-18 |
大蔵製薬株式会社 |
長期間安定なオランザピンの水性医薬製剤
|
|
JP2016525532A
(ja)
|
2013-07-26 |
2016-08-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
骨髄異形成症候群の処置
|
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
|
US9867831B2
(en)
|
2014-10-01 |
2018-01-16 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
|
|
CN109310697A
(zh)
|
2016-06-10 |
2019-02-05 |
勃林格殷格翰国际有限公司 |
利格列汀和二甲双胍的组合
|